Novigenix SA (Novigenix) is a molecular diagnostics company that develops new generation blood tests for early detection of cancer. The company provides lead product such as colox, a molecular blood test designed to reduce the mortality from colorectal cancer through early detection and colonoscopy. It offers colox which is based on the analysis of peripheral blood mononuclear cells that detects both adenomatous polyps and early stages of colorectal cancer. Novigenix provides technology which is based on a new generation of gene expression profiles of circulating blood cells and tumor-derived protein markers. The company caters through its clinical laboratories located in Switzerland. Novigenix is headquartered in Lausanne, Switzerland.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Novigenix SA
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Novigenix SA Company Overview
Novigenix SA Company Snapshot
Novigenix SA Pipeline Products and Ongoing Clinical Trials Overview
Novigenix SA – Pipeline Analysis Overview
Novigenix SA - Key Facts
Novigenix SA - Major Products and Services
Novigenix SA Pipeline Products by Development Stage
Novigenix SA Pipeline Products Overview
LITOSeekColon
LITOSeekColon Product Overview
LITOseekColonMon
LITOseekColonMon Product Overview
LITOSeekProstate
LITOSeekProstate Product Overview
Precision Diagnostic Test - Neuroendocrine Tumor
Precision Diagnostic Test - Neuroendocrine Tumor Product Overview
Novigenix SA - Key Competitors
Novigenix SA - Key Employees
Novigenix SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Affiliate
Recent Developments
Novigenix SA, Recent Developments
Jan 17, 2024: Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling
Jun 30, 2023: Novigenix Reports Interim European Validation Data on Its New NGS-Based Whole Blood RNA Signature for Detection of Advanced Colorectal Adenomas
Sep 09, 2022: Novigenix announces discovery of liquid biopsy immunotherapy response biomarkers in metastatic Melanoma
Sep 23, 2021: Novigenix and Radbound University Medical Center discover the first blood-based ImmunoTranscriptomic biomarkers for Response to anti-PD-1 therapy
Dec 22, 2020: Novigenix-led consortium secures Eurostars funding to develop predictive immune checkpoint inhibitor test
Jan 21, 2020: Novigenix-Led Consortium secures Eurostars Funding to develop multi-omics test for colon cancer detection and monitoring
Dec 11, 2019: Novigenix develops new NGS-based immune cell type specific RNA signatures for early colon cancer detection
Oct 09, 2019: Novigenix receives reimbursement coverage for Colox in Switzerland
Oct 01, 2019: ESMO: Early colon cancer detection blood test yields positive results
Sep 10, 2019: Novigenix to present data on new molecular signature for early detection of colon cancer at ESMO 2019
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Novigenix SA Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Novigenix SA Pipeline Products by Equipment Type
Table 3: Novigenix SA Pipeline Products by Indication
Table 4: Novigenix SA, Key Facts
Table 5: Novigenix SA, Major Products and Services
Table 6: Novigenix SA Number of Pipeline Products by Development Stage
Table 7: Novigenix SA Pipeline Products Summary by Development Stage
Table 8: LITOSeekColon - Product Status
Table 9: LITOSeekColon - Product Description
Table 10: LITOseekColonMon - Product Status
Table 11: LITOseekColonMon - Product Description
Table 12: LITOSeekProstate - Product Status
Table 13: LITOSeekProstate - Product Description
Table 14: Precision Diagnostic Test - Neuroendocrine Tumor - Product Status